Chemotherapy-Induced Nausea and Vomiting: Nursing Assessment and Antiemetic Management | Megha Shah, DNP, FNP, OCN

Chemotherapy-induced nausea and vomiting remains one of the side effects patients fear most when they learn they will need chemotherapy. It is also one of the most manageable, when the right antiemetic regimen is selected based on the emetogenic potential of the regimen, when patient-specific risk factors are assessed, and when nurses teach patients how to use their antiemetics effectively.

This article is a clinical reference for nurses managing CINV in the infusion setting. It is also a resource for patients who want to understand why they are taking the medications they are taking and what to do when nausea breaks through.

The Three Types of CINV

Understanding when nausea occurs in relation to chemotherapy administration is the foundation of effective management.

Acute CINV occurs within 24 hours of chemotherapy administration, typically peaking within the first few hours. It is mediated primarily by the release of serotonin from enterochromaffin cells in the gut, which activates vagal afferents projecting to the vomiting center. This is the phase most effectively controlled by 5-HT3 receptor antagonists.

Delayed CINV occurs more than 24 hours after chemotherapy and can last several days. It is mediated by substance P and neurokinin-1 (NK1) pathways rather than serotonin. Delayed CINV is the phase most often undertreated, and it is the phase most responsible for the nausea patients experience at home on days 2 through 5 of their cycle.

Anticipatory CINV is a conditioned response that develops in patients who have experienced significant acute or delayed nausea in previous chemotherapy cycles. Sights, smells, and the experience of arriving at the infusion center can trigger nausea before a single drug has been administered. Management is primarily behavioral and pharmacologic, and the most effective intervention is prevention of significant CINV in early cycles before anticipatory conditioning becomes established.

Emetogenic Risk: The Starting Point for Antiemetic Selection

The selection of an antiemetic regimen begins with classifying the emetogenic potential of the chemotherapy regimen. This classification is based on the percentage of patients who would be expected to experience emesis without antiemetic prophylaxis.

High emetogenic risk (HEC): Greater than 90% of patients would experience emesis without prophylaxis. This category includes cisplatin (at any dose), cyclophosphamide at high doses, carmustine, and several combination regimens including AC (doxorubicin/cyclophosphamide). Management of HEC requires a three-drug antiemetic regimen: a 5-HT3 antagonist, an NK1 receptor antagonist, and dexamethasone. Some institutional protocols also suggest adding a fourth drug to the antiemetic regimen: olanzapine.

Moderate emetogenic risk (MEC): 30 to 90% of patients would experience emesis without prophylaxis. This category includes carboplatin (at AUC 4 or higher), oxaliplatin, irinotecan, doxorubicin (at lower doses), and others. Management typically requires a 5-HT3 antagonist, dexamethasone, and, increasingly, an NK1 receptor antagonist for the highest-risk MEC agents.

Low emetogenic risk: 10 to 30% of patients. Includes agents such as paclitaxel, docetaxel, etoposide, and gemcitabine. A single antiemetic, typically a 5-HT3 antagonist or dexamethasone, is generally sufficient.

Minimal emetogenic risk: Less than 10% of patients. Includes agents such as vincristine, bleomycin, and methotrexate at low doses. Routine prophylaxis is not typically required, though as-needed antiemetics should be available.

Key Antiemetic Drug Classes

5-HT3 receptor antagonists. This class includes ondansetron (Zofran), granisetron, dolasetron, and palonosetron. Ondansetron is the most commonly used and most familiar to nurses in the infusion setting. It is highly effective for acute CINV. Palonosetron has a longer half-life and some data suggesting activity beyond 24 hours, making it the preferred 5-HT3 agent in higher emetogenic risk settings.

NK1 receptor antagonists. Aprepitant (Emend) and its intravenous prodrug fosaprepitant (Emend IV), along with rolapitant (Varubi) and netupitant (as a combination product with palonosetron, marketed as Akynzeo), block the NK1 receptor pathway that drives delayed CINV. These agents are standard of care for HEC and increasingly used for high-risk MEC regimens. Aprepitant is given orally on days 1 through 3 of the cycle when prescribed; nurses should confirm that patients have the oral supply and understand the dosing schedule before discharge. Most institutional treatment protocols include fosaprepitant as a pre-medication to be administered to the patients in the intravenous formulation.

Corticosteroids. Dexamethasone is a backbone of multimodal antiemetic therapy. Its mechanism in CINV is not fully understood but is thought to involve anti-inflammatory effects and enhancement of antiemetic activity from co-administered agents. It is highly effective and widely used across emetogenic risk categories. Patients receiving dexamethasone should be counseled about blood glucose effects, insomnia, and GI symptoms, particularly if they have diabetes or a history of peptic ulcer disease.

Olanzapine. This atypical antipsychotic has emerged as a meaningful addition to antiemetic regimens for HEC and refractory CINV. It acts on multiple receptor pathways involved in nausea, including dopamine, histamine, and serotonin receptors. ASCO and NCCN guidelines now recommend olanzapine as part of the four-drug regimen for HEC. The primary side effect is sedation, which is clinically relevant, patients should be counseled not to drive after taking it, and the timing relative to bedtime can be adjusted to use the sedation effect productively. Nurses should monitor for orthostatic hypotension, particularly in older adults.

Patient-Specific Risk Factors

Emetogenic potential of the regimen determines the baseline antiemetic approach, but patient-specific factors modify individual risk and should be assessed at every cycle.

Higher individual CINV risk is associated with: female sex, younger age (below 50), history of significant motion sickness, history of nausea during pregnancy, low alcohol use or abstinence, and anxiety about treatment. Patients with multiple risk factors may benefit from a more aggressive antiemetic approach even with lower-risk regimens.

Prior CINV history is one of the most practically important data points to collect. If a patient experienced poorly controlled nausea in a previous cycle, document it specifically, which phase was affected (acute, delayed, or both), what antiemetics were taken and how, and what did and did not help. Use that information to adjust the regimen for the next cycle. Waiting until nausea is severe and entrenched across multiple cycles is harder to reverse than addressing it early.

Nursing Assessment During Infusion

At the start of each infusion appointment, a targeted CINV assessment should include:

How was the nausea and vomiting since the last cycle? Was it primarily in the first 24 hours or after that?
Were the prescribed antiemetics taken as directed? Were there any barriers to taking them, cost, side effects, confusion about timing?
Did the patient require any additional antiemetics beyond what was prescribed? Any emergency department visits for nausea or dehydration?
Current oral intake, weight change, and hydration status.

This assessment is not a formality. It is the mechanism by which CINV management is iteratively improved across a treatment course. Nurses who collect this information consistently and communicate it to the prescribing provider are contributing directly to better symptom control for their patients.

What to Teach Patients Before They Go Home

Before discharge from each infusion, patients receiving moderate or high emetogenic risk regimens should be able to state:

Which antiemetic to take first, and when, the scheduled antiemetics should be taken proactively, not only when nausea starts.
What the schedule is for each medication over the following days.
What to do if breakthrough nausea occurs despite scheduled antiemetics, which rescue medication to use, and when it is appropriate.
At what point to call the clinic: inability to keep fluids down for more than 12 to 24 hours, signs of dehydration, or nausea that is not responding to rescue antiemetics.

A written schedule that lists medications by name, dose, and timing, rather than simply saying “take your anti-nausea medication”, significantly improves adherence. Patients who are nauseated and anxious are not well-positioned to parse ambiguous instructions.

Non-pharmacologic strategies worth discussing with patients: small, frequent, bland meals rather than large meals; avoidance of strong food odors during the delayed CINV period; cold or room-temperature foods, which are generally less odorous than hot foods; ginger products (ginger chews, ginger tea) as an adjunct; and acupressure wristbands, which have modest evidence and minimal harm.

CINV is manageable. That statement was not true two decades ago, and it is true now in large part because of advances in antiemetic pharmacology and because of nurses who assess systematically, teach thoroughly, and communicate what they find to the team. That is not a small contribution. It is the clinical infrastructure that good symptom management depends on.